Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform

Eli Lilly & Company (NYSE:LLY) ranks among the best high profit margin stocks to buy. Following the reveal of an innovative employer access platform for obesity therapies, Morgan Stanley reiterated its Overweight rating and $1,313 price target for Eli Lilly & Company (NYSE:LLY) on March 5. Eli Lilly recently established its Employer Connect platform in the US, which provides flexible benefit designs geared at increasing access to obesity treatments like Zepbound.

Pixabay/Public Domain

In order to produce solutions that enhance employee access to obesity management medications, the platform facilitates collaboration with independent program administrators.

According to Morgan Stanley, the update may facilitate future development in US volume and provide Zepbound with another commercial access route. The firm also anticipates contributions from the introduction of Orfor, an oral GLP-1 therapy, in April, as well as increased Medicare access in the latter half of the year.

In a related development, Eli Lilly & Company (NYSE:LLY) stated that its Orfor therapy outperformed oral semaglutide in a Type 2 diabetes trial, meeting all primary and significant secondary goals.

Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.